2,115 press releases in English indexed under biotech & pharma.
Dublin, Oct. 22, 2026 -- "AI in Clinical Trials Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report (2026-2035)" has been added to ResearchAndMarkets.com's offering.
Vera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA in IgAN at ASN 2026 and Published in NEJM
The global trisodium citrate market is gaining steady momentum as food and beverage manufacturers, pharmaceutical companies, and industrial producers seek versatile ingredients for product formulation and processing. Trisodium citrate, also known as sodium citrate, is the sodium salt of citric ... Read more
Part D plan remains one of the nation's highest-rated PBM-sponsored EGWP offerings MADISON, Wis., October 22, 2026--For the 11th consecutive year, Navitus MedicareRx has earned the nation's highest rating among Prescription Drug Plan (PDP) and Employer Group Waiver Plan (EGWP) offerings, receiving a 4
NeOnc (NASDAQ: NTHI) is taking its brain cancer story to Fox Business Network when several developments put the clinical-stage biotech in the spotlight
Identify cost-efficient trial locations, investment priorities and business opportunities while benchmarking enrollment trends and trial success to sharpen competitive strategy. Identify cost-efficient trial locations, investment priorities and business opportunities while benchmarking enrollment trends and trial success to sharpen competitive strategy.
Identify cost-efficient trial locations, investment opportunities and enrollment trends to sharpen strategy and gain a competitive advantage. Identify cost-efficient trial locations, investment opportunities and enrollment trends to sharpen strategy and gain a competitive advantage.
Optimize trial investment by identifying cost-efficient locations, key business opportunities, enrollment trends and competitive strategies across global markets. Optimize trial investment by identifying cost-efficient locations, key business opportunities, enrollment trends and competitive strategies across global markets.
Identify trial locations that save time and cost, uncover investment opportunities, and shape competitive strategies with global trial, enrollment and success rate insights. Identify trial locations that save time and cost, uncover investment opportunities, and shape competitive strategies with global trial, enrollment and success rate insights.
TORONTO, ONTARIO - October 22, 2026 - NeuroThera Labs Inc. (TSXV: NTLX) (the "Company" or "NeuroThera"), a clinical-stage pharmaceutical company and a subsidiary of SciSparc Ltd., today announced further progress in its U.S. Food and Drug Administration (“FDA”) approved clinical trial program evaluating SCI-110 for the treatment of Tourette Syndrome (“TS”) in adults. The Company has successfully completed the manufacturing of the investigational product and obtained the required batch release certification from a European Qualified Person (“QP”), a key regulatory milestone authorizing shipment of clinical trial material to participating study sites. The release enables site activation activities and supports the initiation of patient enrollment in the FDA-approved Phase IIb clinical trial for TS. The Phase IIb clinical trial is being conducted at three clinical sites: Yale Child Study Center at Yale School of Medicine in New Haven, Connecticut, USA; Hannover Medical School in Hanover, Germany; and Tel Aviv Sourasky Medical Center in Tel Aviv, Israel. All participating sites have successfully completed their site initiation activities and are prepared to receive clinical trial drug supplies following QP batch release. Completion of site initiation activities across all participating clinical centers, together with the successful European QP release of clinical trial supplies, marks a significant operational milestone for NeuroThera. The Company is now advancing toward patient enrollment in its Phase IIb clinical trial for TS, with investigational product shipments to study sites expected in the near term. SCI-110 is NeuroThera’s proprietary, patent-protected cannabinoid-based drug candidate, combining dronabinol and palmitoylethanolamide (PEA) in a single oral dosage form. The Phase IIb study is evaluating SCI-110's efficacy, safety and tolerability in adults with TS, a condition with substantial unmet treatment needs. About NeuroThera Labs Inc. NeuroTheraLabsInc. (TSXV:NTLX) is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations. For further information, please contact: Michal Efraty IR Manager NeuroThera Labs Inc. Telephone: +972-3-7617108 Email: michal@efraty.com Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. Cautionary Notice on Forward-Looking Statements This news release contains statements that constitute "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking information and are based on expectations, estimates and projections as at the date of this news release. Forward-looking information in this news release includes statements regarding: the initiation of patient enrollment in the Phase IIb clinical trial for TS; the expected timing for investigational product shipments to study sites; and the potential efficacy, safety and tolerability of SCI-110. These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking information necessarily involves known and unknown risks and uncertainties, which may cause the Company's actual performance and results to differ materially from any projections of future performance or results expressed or implied by such forward-looking information. Such factors include, without limitation: the ability of the Company to progress toward patient enrollment for its Phase IIb clinical trial for TS; and the other risks described in the Company's continuous disclosure documents filed on SEDAR+ (www.sedarplus.ca). The Company does not undertake any obligation to update or revise any forward-looking information, except as required by applicable securities laws.
FORT LAUDERDALE, FL / October 22, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company specializing in generic and specialty prescription medications, including drugs in the areas of oncology and antivirals, today announced a one for twenty reverse split of its common st
ANTWERPEN, BELGIUM, Oct 22, 2026 - OMP, a leader in AI-powered supply chain solutions, recently honored six global brands at its conferences held earlier this month in Singapore and Shanghai. The recognized companies - Procter & Gamble (P&G), Nestlé, Mars, AstraZeneca, ITC, and Bekaert - were celebrated for driving decision velocity, co-innovation, and impactful business results. Supply Chain Innovation & Excellence Award: Nestlé and Bekaert Nestlé, one of the world's largest food and beverage companies, and Bekaert, a global market and technology leader in material science of steel wire transformation and coating technologies, received OMP's Supply Chain Innovation & Excellence award for their breadth of deployment and depth of co-innovation. Nestlé aligns its supply network at the strategic, tactical, and operational levels on OMP's Unison Planning™ platform, connecting forecasting, planning, and replenishment end-to-end. As more routine work becomes touchless, planners can focus on the decisions that drive the business, and Nestlé continues to roll out best practices throughout the organization. Bekaert integrated scenario planning directly into its S&OP, shifting teams from reactive firefighting to proactive, value-driven conversations. In its green hydrogen business, what-if modeling protects mid- and long-term strategic control. Furthermore, planners use Unison Companion, OMP's generative AI assistant, to generate tables, compare scenarios, and retrieve information in natural language. "This award recognizes the ongoing transformation of our end-to-end supply chain planning," says Bo Yang, Senior Manager, Global Supply Chain Process Management at Bekaert Rubber Reinforcement. "We've moved from manual Excel calculations and individual experience to standardized planning on OMP's Unison Planning™ platform. Our decisions are now backed by data, and our planning accuracy has improved significantly." Long-Term Partnership Award: P&G and AstraZeneca P&G, with operations in approximately 70 countries, joins global biopharma leader AstraZeneca in accepting the award for proving that value compounds the longer the partnership runs. P&G celebrates 27 years of partnership with OMP dating back to 1999, and operates a planning network spanning more than 100 manufacturing sites and 200 distribution centers. The company has consolidated overlapping planning processes, with the majority of planning now handled touchlessly. "Receiving OMP's Long-Term Partnership Award reflects years of trust and teamwork between our teams," says Jen Aberilla, Director, Regional Supply Network Operations Planning at P&G. "We're proud of what we've achieved together and look forward to building on it." AstraZeneca has been working with OMP since 2021, replacing siloed, spreadsheet-based planning with a single capacity-constrained network plan. Most recently, the company has been collaborating with OMP on AI‑driven planning and advanced scenario modeling, allowing planners to focus on scenarios and exceptions. This has resulted in improved supply reliability and service levels, inventory reduction, and productivity savings. Community Engagement Award: Mars and ITC ITC's Paperboards & Specialty Papers Division, part of the Indian multi-business enterprise ITC Limited, and Mars, a global giant in confectionery, food products, and pet care services, received the Community Engagement Award for their active role in OMP Community events and councils. ITC was recognized for its commitment to openly sharing its planning transformation with the wider supply chain community. By presenting its experience to industry peers, ITC has given them a candid look at how its journey unfolds in practice, with lessons other planning teams can apply. Mars is a committed participant in the OMP Community councils and in governance through the executive board. Working with OMP, Mars has lowered inventory, consolidated its warehouse network, improved factory equipment effectiveness, and increased forecast accuracy. "The world's most demanding manufacturers plan with OMP, and it is a privilege to see those relationships deepen over 10, 20, and 27 years. The results they achieve through this community are concrete: inventory goes down, forecast accuracy goes up, and decisions happen faster. Congratulations to each of them!" says Philip Vervloesem, Chief Commercial and Markets Officer at OMP. About OMP OMP helps companies facing complex planning challenges to excel, grow and thrive by offering the best digitized supply chain planning solution on the market. Hundreds of customers in a wide range of industries - spanning consumer goods, life sciences, chemicals, metals, paper and packaging - benefit from using OMP's unique Unison Planning™. Solution and product inquiries Contact OMP +32 3 650 22 11 Media inquiries Kira Perdue (Carabiner) SOURCE: OMP